Seres Therapeutics Inc
MCRB13.860USD
+1.160+9.13%
Cierre 11/06, 16:00（ET）Cotizaciones retrasadas 15 min
121.48MCap. mercado
22.52P/E TTM
Más Datos de Seres Therapeutics Inc Compañía
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.
Información de Seres Therapeutics Inc
Símbolo de cotizaciónMCRB
Nombre de la empresaSeres Therapeutics Inc
Fecha de salida a bolsaJun 26, 2015
Director ejecutivoMr. Thomas J. DesRosier, J.D.
Número de empleados103
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 26
Dirección101 Cambridge Park Drive
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02140
Teléfono16179459626
Sitio Webhttps://www.serestherapeutics.com/
Símbolo de cotizaciónMCRB
Fecha de salida a bolsaJun 26, 2015
Director ejecutivoMr. Thomas J. DesRosier, J.D.
Ejecutivos de Seres Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.46K
+2.31%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.55K
+3.76%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
--
--
Dr. Claire M. Fraser, Ph.D.
Dr. Claire M. Fraser, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Co-President, Co-Chief Executive Officer, Chief Financial Officer
Co-President, Co-Chief Executive Officer, Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.46K
+2.31%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
4.55K
+3.76%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
FY2023
FY2022
FY2021
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
126.33M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Flagship Ventures
13.20%
Nestle SA
12.44%
The Vanguard Group, Inc.
3.34%
Fidelity Management & Research Company LLC
3.05%
Bank Vontobel AG
1.13%
Otro
66.84%
Accionistas
Accionistas
Proporción
Flagship Ventures
13.20%
Nestle SA
12.44%
The Vanguard Group, Inc.
3.34%
Fidelity Management & Research Company LLC
3.05%
Bank Vontobel AG
1.13%
Otro
66.84%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
13.46%
Corporation
12.44%
Investment Advisor
8.34%
Investment Advisor/Hedge Fund
2.92%
Research Firm
1.21%
Individual Investor
0.57%
Hedge Fund
0.36%
Bank and Trust
0.05%
Otro
60.66%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
253
2.30M
26.32%
-2.29M
2025Q2
284
4.24M
48.50%
-1.01M
2025Q1
303
4.22M
48.29%
-1.11M
2024Q4
311
85.93M
50.33%
-20.68M
2024Q3
330
86.09M
50.57%
-26.54M
2024Q2
336
69.70M
45.95%
-51.91M
2024Q1
345
94.53M
65.81%
-35.72M
2023Q4
345
98.23M
75.49%
-30.72M
2023Q3
356
117.05M
93.47%
-19.47M
2023Q2
384
121.97M
97.71%
-18.66M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Flagship Ventures
1.16M
13.2%
-2.00
-0.00%
Jun 30, 2025
Nestle SA
1.09M
12.44%
+709.39K
+186.83%
Sep 30, 2024
The Vanguard Group, Inc.
292.10K
3.34%
-12.50K
-4.11%
Jun 30, 2025
Fidelity Management & Research Company LLC
267.07K
3.05%
-825.67K
-75.56%
Jun 30, 2025
Bank Vontobel AG
80.33K
0.92%
+26.03K
+47.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
97.67K
1.12%
+13.57K
+16.13%
Jun 30, 2025
Geode Capital Management, L.L.C.
91.60K
1.05%
+10.66K
+13.17%
Jun 30, 2025
Marshall Wace LLP
91.41K
1.04%
+91.41K
--
Jun 30, 2025
Charles Schwab Investment Management, Inc.
34.88K
0.4%
-6.83K
-16.37%
Jun 30, 2025
State Street Investment Management (US)
26.83K
0.31%
+1.79K
+7.17%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: hace 17 horas
Actualizado: hace 17 horas
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Schwab U.S. Small-Cap ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
iShares Russell 3000 ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
